[go: up one dir, main page]

MX9303977A - Composicion farmaceutica y metodo para el mejoramiento de la capacitacion de una sustancia farmacologicamente activa a traves de las membranas mucosas de un animal. - Google Patents

Composicion farmaceutica y metodo para el mejoramiento de la capacitacion de una sustancia farmacologicamente activa a traves de las membranas mucosas de un animal.

Info

Publication number
MX9303977A
MX9303977A MX9303977A MX9303977A MX9303977A MX 9303977 A MX9303977 A MX 9303977A MX 9303977 A MX9303977 A MX 9303977A MX 9303977 A MX9303977 A MX 9303977A MX 9303977 A MX9303977 A MX 9303977A
Authority
MX
Mexico
Prior art keywords
animal
improvement
pharmacologically active
mucous membranes
training
Prior art date
Application number
MX9303977A
Other languages
English (en)
Inventor
Charlotte A Kensil
Sean Soltysik
Dante J Marciani
Original Assignee
Cambridge Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotech Corp filed Critical Cambridge Biotech Corp
Publication of MX9303977A publication Critical patent/MX9303977A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los métodos para el mejoramiento del transporte de substancias farmacológicamente activas a través de las membranas mucosas de un animal, mediante la administración de composiciones farmacéuticas que comprenden saponinas modificadas o fracciones de las mismas, obtenibles mediante modificación de un extracto de Quillaja saponaria crudo, o mediante modificación de saponinas purificadas obtenibles de un extracto crudo de Quillaja saponaria. También se describen las saponinas modificadas que tienen irritabilidad reducida, en donde la porción de ácido graso se elimina mediante hidrólisis o se reduce el grupo aldehído. También se describen las composiciones farmacéuticas que comprenden las saponinas modificadas de la invención.
MX9303977A 1992-07-02 1993-07-01 Composicion farmaceutica y metodo para el mejoramiento de la capacitacion de una sustancia farmacologicamente activa a traves de las membranas mucosas de un animal. MX9303977A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/906,870 US5273965A (en) 1992-07-02 1992-07-02 Methods for enhancing drug delivery with modified saponins

Publications (1)

Publication Number Publication Date
MX9303977A true MX9303977A (es) 1994-04-29

Family

ID=25423119

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9303977A MX9303977A (es) 1992-07-02 1993-07-01 Composicion farmaceutica y metodo para el mejoramiento de la capacitacion de una sustancia farmacologicamente activa a traves de las membranas mucosas de un animal.

Country Status (11)

Country Link
US (2) US5273965A (es)
EP (1) EP0658111B1 (es)
JP (1) JP3684370B2 (es)
AU (1) AU687005B2 (es)
BR (1) BR9306594A (es)
CA (1) CA2139437A1 (es)
DE (1) DE69326772T2 (es)
FI (1) FI946173L (es)
HU (1) HUT73814A (es)
MX (1) MX9303977A (es)
WO (1) WO1994001118A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US5780444A (en) * 1991-12-13 1998-07-14 Trustees Of Princeton University Compositions and methods for cell transformation
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
ES2290074T3 (es) 1993-07-19 2008-02-16 Angiotech Pharmaceuticals, Inc. Composiciones anti-angiogenicas que contienen taxol y un vehiculo no biodegradable y su uso.
KR970701043A (ko) * 1994-02-25 1997-03-17 데이비드 키즈키스 항-염증성 및 감염 보호 효과를 갖는 세사민-기본 리그난(anti-inflammatory and infection protective effects of sesamin-based lignans)
US5397778A (en) * 1994-02-25 1995-03-14 New England Deaconess Hospital Corporation Enteral formulations for treatment of inflammation and infection
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
AU773686B2 (en) * 1996-02-21 2004-06-03 Intarcia Therapeutics, Inc. Use of cell membrane permeants in the treatment of cellular proliferative diseases
AU2275697A (en) * 1996-02-21 1997-09-10 Matrix Pharmaceutical, Inc. Use of cell membrane permeants in the treatment of cellular proliferative disea ses
AU730230B2 (en) * 1996-12-02 2001-03-01 Aquila Biopharmaceuticals, Inc. Novel saponin compositions and uses thereof
US6471943B1 (en) 1996-12-30 2002-10-29 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
BR9809149A (pt) * 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US8765177B2 (en) 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
US20070059327A2 (en) * 1998-01-15 2007-03-15 Wyeth Streptococcus equi compositions and methods of use
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
CA2328946C (en) 1998-04-17 2008-02-12 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for recovery and purification of saponins and sapogenins from quinoa (chenopodium quinoa)
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
ATE315405T1 (de) 1998-08-10 2006-02-15 Antigenics Inc Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
CA2362204C (en) 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
ES2311478T3 (es) * 1999-11-19 2009-02-16 Csl Limited Composiciones de vacuna contra el hcv.
CZ304942B6 (cs) * 2000-03-31 2015-02-04 Purdue Research Foundation Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl
JP2004505894A (ja) 2000-06-02 2004-02-26 ユニバーシティー　オブ　コネティカット　ヘルス　センター 免疫療法のためのα（２）マクログロブリンと抗原分子との複合体
WO2002011669A2 (en) * 2000-08-07 2002-02-14 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
ATE409495T1 (de) 2001-04-04 2008-10-15 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten
KR20040015234A (ko) * 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 대식세포 매개된 질환의 치료와 진단
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
DK1434603T3 (da) * 2001-09-28 2010-04-26 Purdue Research Foundation Fremgangsmåde til behandling ved anvendelse af ligand-immunogen-konjugater
AU2002357359B2 (en) * 2001-12-21 2009-01-08 Csl Limited Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
WO2004092329A2 (en) * 2003-04-08 2004-10-28 Galenica Pharmaceuticals, Inc. Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US20050175623A1 (en) * 2004-02-10 2005-08-11 Zheng-Pin Wang Saponins as anticancer agent
BRPI0507680A (pt) * 2004-02-13 2007-07-17 Nod Pharmaceuticals Inc partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
US20080287662A1 (en) * 2005-06-22 2008-11-20 Zeev Wiesman Balanites Aegyptiaca Saponins and Uses Thereof
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
CA2692221A1 (en) * 2007-06-27 2008-12-31 Coloplast A/S Treatment of urinary tract infections with a mixture of saponin and an antibiotic
EP2222328A4 (en) * 2007-11-15 2013-06-05 Endocyte Inc PROCESS FOR THE ADMINISTRATION OF CONJUGATES
CN102946900A (zh) 2010-03-11 2013-02-27 免疫设计公司 用于大流行流感的疫苗
US9332776B1 (en) 2010-09-27 2016-05-10 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
US8939388B1 (en) 2010-09-27 2015-01-27 ZoomEssence, Inc. Methods and apparatus for low heat spray drying
SG192759A1 (en) 2011-02-15 2013-09-30 Immune Design Corp Methods for enhancing immunogen specific immune responses by vectored vaccines
JP2014515597A (ja) 2011-03-04 2014-07-03 インターナショナル フレーバーズ アンド フラグランシズ インコーポレイテッド 揮発性化合物を保持することができる噴霧乾燥組成物および該組成物を製造する方法
US20130022728A1 (en) * 2011-03-04 2013-01-24 International Flavor & Fragrances Inc. Spray-Dried Compositions Capable of Retaining Volatile Compounds and Methods of Producing the Same
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
MX2016009464A (es) 2014-01-21 2017-01-16 Immune Design Corp Composiciones para el uso en el tratamiento de afecciones alergicas.
EP3104878B1 (en) 2014-02-14 2019-05-22 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
WO2016011083A1 (en) 2014-07-15 2016-01-21 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
US20200115324A1 (en) 2017-06-11 2020-04-16 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
US10155234B1 (en) 2017-08-04 2018-12-18 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10486173B2 (en) 2017-08-04 2019-11-26 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US9993787B1 (en) 2017-08-04 2018-06-12 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US9861945B1 (en) 2017-08-04 2018-01-09 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
CA3071115C (en) 2017-08-04 2022-06-21 ZoomEssence, Inc. Ultrahigh efficiency spray drying apparatus and process
US10569244B2 (en) 2018-04-28 2020-02-25 ZoomEssence, Inc. Low temperature spray drying of carrier-free compositions
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
WO2021014026A2 (en) * 2019-07-25 2021-01-28 Sapreme Technologies B.V. Bioactive saponin linked to a functional moiety
KR20220149505A (ko) 2019-12-03 2022-11-08 누보젠 인코포레이티드 종양 세포 백신
US20230117744A1 (en) 2020-03-23 2023-04-20 Loyola University Of Chicago Coronavirus vaccines compositions and method of using same
EP4171644A2 (en) * 2020-06-24 2023-05-03 Sapreme Technologies B.V. Saponin derivatives for use in medicine
IL299356A (en) * 2020-06-24 2023-02-01 Sapreme Tech Bv Hydrazone-based saponin derivatives
EP4236995A2 (en) 2020-11-02 2023-09-06 Neuvogen, Inc. Tumor cell vaccines
CN113480985A (zh) * 2021-07-07 2021-10-08 东营煜煌能源技术有限公司 一种微纳米膨胀胶束弹性颗粒驱油乳液制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD160763A3 (de) * 1978-06-05 1984-03-07 Loeffler Friedrich Inst Verfahren zur herstellung von konzentratvakzinen
FR2456116A1 (fr) * 1979-05-11 1980-12-05 Sarget Lab Nouvelle saponine triterpenique derivee de la caulophyllogenine et ses applications therapeutiques
GB2064320B (en) * 1979-10-13 1983-10-12 Welsh Nat School Med Intra-ocular irrigation fluid
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
JPS62126135A (ja) * 1985-11-25 1987-06-08 Sumitomo Pharmaceut Co Ltd 経鼻投与用ｇｒｆ製剤
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US5166139A (en) * 1987-02-26 1992-11-24 Indena, S.P.A. Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5118676A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5118692A (en) * 1988-04-08 1992-06-02 Whitby Research, Inc. Penetration enhances for transdermal delivery of systemic agents
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye

Also Published As

Publication number Publication date
AU687005B2 (en) 1998-02-19
JPH07509440A (ja) 1995-10-19
WO1994001118A1 (en) 1994-01-20
DE69326772D1 (de) 1999-11-18
EP0658111A4 (en) 1996-02-07
JP3684370B2 (ja) 2005-08-17
FI946173L (fi) 1995-02-15
US5273965A (en) 1993-12-28
US5443829A (en) 1995-08-22
EP0658111B1 (en) 1999-10-13
HUT73814A (en) 1996-09-30
EP0658111A1 (en) 1995-06-21
BR9306594A (pt) 1998-12-08
AU4664993A (en) 1994-01-31
CA2139437A1 (en) 1994-01-20
FI946173A0 (fi) 1994-12-30
DE69326772T2 (de) 2000-06-29
HU9500001D0 (en) 1995-03-28

Similar Documents

Publication Publication Date Title
MX9303977A (es) Composicion farmaceutica y metodo para el mejoramiento de la capacitacion de una sustancia farmacologicamente activa a traves de las membranas mucosas de un animal.
US4474798A (en) Pharmaceutical preparation for endermic application
AR030254A1 (es) Uso de un componente de neurotoxina clostridial acoplado a una fraccion objetivo para preparar una composicion farmaceutica de utilidad para tratar un tumor oseo
ES2195175T3 (es) Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
PE799A1 (es) Composicion cosmetica que contiene un antagonista de los receptores del neuropeptido y
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
ATE526956T1 (de) Viruzide zusammensetzungen
ATE13286T1 (de) Pharmazeutisch aktive phenylcarbonsaeurederivate.
ES2099428T3 (es) Composiciones farmaceuticas para inhalacion.
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
JP3725557B2 (ja) 抗アクネ活性を有する薬剤および化粧用調製物
EP0472531A1 (fr) Composition a base de proanthocyanidols; leur application pharmacologique.
ES2032405T3 (es) Derivados de los acidos valproico y (e)-2-valproenoico, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2053575T3 (es) Lipasas y extractos lipasicos, su procedimiento de preparacion y su aplicacion en terapeutica.
EP1383540A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR Wounds Healing
US7993683B2 (en) Compositions for the treatment of chronic degenerative inflammatory conditions
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
FR2461499A1 (fr) Composition pharmaceutique a base d'extraits de myrtille
AR012546A1 (es) Utilizacion de al menos un compuesto seleccionado entre el grupo que comprende los sogaoles y los gingeroles para la preparacion de una composiciondesodorante, sogaol, extracto bruto y extracto purificado que contiene el sogaol y la composicion desodorante obtenida.
NO306762B1 (no) Anvendelse av lanolinderivater sammen med polyetylenglykoletere, blanding derav og transdermalt terapeutisk system
CO4790151A1 (es) COMPOSICIONES QUE COMPRENDEN UN INHIBIDOR DE LA PROTEASA DEL VIH COMO VX478 Y UN COMPUESTO DE VITAMINA E sOLUBLE EN AGUA COMO VITAMINA E - TPGS
ATE226438T1 (de) Bioaktives konzentrat,dessen herstellungs- verfahren und bestimmte arzneimittel,die ebenfalls chondroitinsulfat enthalten
FR2831444A1 (fr) Compositions cosmetiques ou dermatologiques pour le soin de la peau contenant un extrait de buddleja et un extrait d'anthyllis
DK225986D0 (da) Farmaceutisk komposition af promedikamenttypen og fremgangsmaade til fremstilling af samme

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees